Neuroendocrine prostate cancer: long noncoding RNAs to treat an incurable cancer – an interview with Dr Francesco Crea

Crea, Francesco (2019). Neuroendocrine prostate cancer: long noncoding RNAs to treat an incurable cancer – an interview with Dr Francesco Crea. Epigenomics, 11(13) pp. 1461–1462.

DOI: https://doi.org/10.2217/epi-2019-0236

Abstract

Francesco Crea speaks to Lucy Chard, Commissioning Editor. Dr Crea’s lab studies the role of epigenetic factors and noncoding RNA in cancer initiation and progression. While working at the National Cancer Institute (USA), Dr Crea has demonstrated that polycomb-targeting drugs eradicate prostate cancer stem cells. While working at the BC Cancer Agency (Canada), Dr Crea discovered and patented PCAT18, a long noncoding RNA involved in prostate cancer metastasis. Dr Crea has received awards from the American Society of Clinical Oncology, from the Prostate Cancer Program and from Prostate Cancer Foundation BC. He is also an Editorial Board member for Epigenomics. His team is currently working on developing new biomarkers and therapeutic targets for incurable prostate and breast cancers.

Viewing alternatives

Metrics

Item Actions

Export

You can export this page using these formats Digital Object Identifier - DOI

About

• Item ORO ID
• 66817
• Item Type
• Journal Item - Other
• ISSN
• 1750-192X
• Extra Information
• Interview
• Keywords
• Interview; cancer therapeutics; epigenomics; lncRNA; metastasis; neuroendocrine prostate cancer; patient outcomes
• Academic Unit or School
• Faculty of Science, Technology, Engineering and Mathematics (STEM) > Life, Health and Chemical Sciences
  Faculty of Science, Technology, Engineering and Mathematics (STEM)
• Research Group
• Cancer Research Group
• Copyright Holders
• © 2019 Future Medicine Ltd
• SWORD Depositor
• Jisc Publications-Router
• Depositing User
• Jisc Publications-Router